Laboratorio Reig Jofre, S.a. · BME:RJF
Laboratorio Reig Jofre — Reig Jofre — Q3 2024 Earnings Presentation
17 slides from Laboratorio Reig Jofre's earnings presentation, 2024
Slide 1: Financial Results Third Quarter 2024
FINANCIAL RESULTS THIRD QUARTER 2024 PHARMA SECTOR
Slide 2: Statement
STATEMENT This presentation does not contain confidential material and may include publicly available market information that has not been independently verified by Reig Jofre. This information is given in summary form and does not purport to be complete. The information contained in this presentati
Slide 3: Table of Contents
TABLE OF CONTENTS 3Q 2024 Results → Results statement and balance sheet for 3Q 2024 → Evolution of RJF shares → Forecast 2024 3
Slide 4: Results Third Quarter 2024: revenues grow 7% and EBITDA 10%
RESULTS THIRD Reig Jofre’s revenues grow 7% and its EBITDA 10% QUARTER 2024 Sed ut perspiciatis SALES → Sales figures for the first nine months of 2024 increased by 7% compared to the same period in 2023, continuing the trend of the first half of 2024 fiscal year. The medical products division, Spec
Slide 5: 3Q 2024 Revenues by Business Unit
3Q 2024 REVENUES BY BUSINESS UNIT PHARMACEUTICAL SPECIALTY CONSUMER TECHNOLOGIES PHARMACARE HEALTHCARE Antibiotics Osteoarticular OTC / Energy / Stress and Injectables / Lyophilised Dermatology sleep / Weight control / Beauty +7% +12% -1% €111.5M 44% €85.3M 34% € 5 6 . 2M 22% → Both demand for antib
Slide 6: International Developments
INTERNATIONAL SPAIN Sed ut perspiciatis Rest of EUROPE Sed ut perspiciatis Rest of WORLD DEVELOPMENTS 42% 47% 11% €105.5 M €119.2 M €28.3 M → International markets grew by +15% and represent 58% of total sales. -1% +17% -3% Rest of Europe 47% → Spain maintained steady sales but DIRECT SALES reduced
Slide 7: Table of Contents
TABLE OF CONTENTS → 3Q 2024 Results Results statement and balance sheet for 3Q 2024 → Evolution of RJF shares → Forecast 2024 7
Slide 8: Results Statement 3Q2024
RESULTS STATEMENT 3Q2024 INCOME STATEMENT (thousand euros) 30/09/2023 30/09/2024 V% → Sales figures increased by 7% with an associated gross margin of 59%, Turnover 237.282 253.023 7% +1.2 basis points compared to the previous year. Procurements -103.077 -104.273 4% Changes in inventories 3.133 783
Slide 9: Balance Sheet: Assets and Investments
BALANCE SHEET INVESTMENT 3Q24 ASSETS AND INVESTMENTS 30/09/2024 € 13.6 M € 3.7 M BALANCE SHEET (thousand euros) 31/12/2023 30/09/2024 Biotechnology Goodwill 27.985 27.885 Assets Other intangible assets 63.070 57.568 Property, plant and equipment 91.625 94.726 3,7 Investments in equity-accounted inve
Slide 10: Balance Sheet: Liabilities and Debt
BALANCE SHEET INVESTMENT 2023 LIABILITIES AND DEBT 30/09/2024 NET FINANCIAL DEBT DEBT / EBITDA 3Q 3Q BALANCE SHEET (thousand euros) 31/12/2023 30/09/2024 2024 €63.0 M 2024 1.7x TOTAL EQUITY 204.254 212.068 3T 3T Capital grants Provisions 3.571 199 4.053 199 2023 €59.5 M 2023 1.7x Financial liabiliti
Slide 11: Table of Contents
TABLE OF CONTENTS → 3Q 2024 Results → Results statement and balance sheet for 3Q 2024 Evolution of RJF shares → Forecast 2024 1 1
Slide 12: Evolution of Shares RJF
EVOLUTION OF SHARES RJF YTD SEPTEMBER 24 MARKET CAPITALIZATION €220 M VOLUME CASH VALUATION RJF (ISIN ES0165359029) €2.72/Share - 30/09/2024 maximum minimum 3.3 M €9.2 M → IBEX SMALL CAP component €2.77/Share €3.20/Share €2.29/Share YTD Titles YTD Weighted average 19/01/2024 €48 k SHAREHOLDER COMPOS
Slide 13: Table of Contents
TABLE OF CONTENTS → 3Q 2024 Results → Results statement and balance sheet for 3Q 2024 → Evolution of RJF shares Forecast 2024 1 3
Slide 14: Projections 2024
PROJECTIONS 2024 OPPORTUNITIES RISK UNGUEAL INFLATION RISING GROWTH IN THERAPIES → We anticipate more contained WAGE COSTS IN INJECTABLES AND FRANCHISE sales growth in 2024 than in SPAIN FREEZE – DRIED CYCLE-TECH previous years in order to PRODUCTS increase profitability in the medium and long term
Slide 15: Links and Complementary Information
LINKS AND INFORMATION COMPLEMENTARY → RESULTS WEBCAST https://reigjofre.com/es/inversores/webcasts/ → NEWSLETTER RJF https://reigjofre.com/es/inversores/presentaciones/ http://www.reigjofre.com/es/noticias/centro-suscripcion → INVESTORS FINANCIAL AND OTHER RELEVANT INFORMATION https://reigjofre.com/
Slide 16: Alternative Performance Measures
REIG JOFRE Alternative performance measures Sed ut perspiciatis Management uses certain alternative performance measures in making financial, operating and planning decisions, as well as to evaluate the performance of the Group and its subsidiaries. Management believes that these alternative perform
Slide 17: Thank You
3Q 2024 THANK YOU Gran Capità 10 08970 Sant Joan Despí BARCELONA, SPAIN T. +34 93 480 67 10 www.reigjofre.com Investor Relations investors@reigjofre.com